Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 715

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 715
---
 in consideration for any Sublicense granted for the Licensed Products to include: •15% of all Net Amounts earned by Sublicensee in the Territory if the Patent covers the Licensed Products •5% of all Net Amounts in case the Aexon Labs Patent is not granted yet •If any sublicensee challenges the validity of the patent, the new royalty rate doubles to 30% if the validity of Aexon’s patent is confirmed by the relevant patent office. Recent Advancements On June 2024 the Company announced preclinical results from multiple in vitro studies targeting alpha -synuclein( α -synuclein), specifically the A53T mutation, that demonstrate the compounds’ potential to advance the treatment of Parkinson’s Disease (PD). The compounds may be used by NLS pursuant to its license agreement with Aexon Labs, Inc. Using the “Alpha -Synuclein( α -synuclein) A53T Parkinson’s Disease Genetic Cell -BasedAgonist Neurite Outgrowth Assay” by Eurofins, various DOXA compounds demonstrated positive effects on neurite outgrowth, a critical parameter of neuronal health and regeneration. Neurite outgrowth, a critical parameter of neuronal health, was measured using high -contentimaging systems to determine the efficacy of AEX compounds. Reducing α -synucleinaggregation or promoting its clearance can alleviate its toxic effects on neurons. The effects of AEX compounds on neurite outgrowth as well as their impact on Cathepsin D (CTSD) and Orexin 1 Receptor (OX1R) activities provide insights into their potential to modulate the impact of α -synuclein. Key findings • AEX -23: Its pronounced action as an OX1R agonist combined with positive effects on neurite outgrowth at specific concentrations suggests that it may modulate neuronal health through pathways influencing α -synucleindynamics, making it a potential therapeutic candidate to improve neuronal connectivity and resilience in PD. • AEX -19: Its effects at low concentrations on neurite growth coupled with OX1R agonist activity and a moderate increase in CTSD activity suggest potential neuroprotective benefits in PD. • AEX -24: The increase in CTSD activity and agonist activity on OX1R suggests the potential to enhance α -synucleindegradation, highlighting its promising therapeutic impact on PD.

| Moore Financial Consulting |

Annex E-40

AEX -23and AEX -19,